Stolper Co Trims Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Share on StockTwits

Stolper Co lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 1.8% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 27,426 shares of the company’s stock after selling 489 shares during the period. Johnson & Johnson comprises 2.5% of Stolper Co’s portfolio, making the stock its 11th largest position. Stolper Co’s holdings in Johnson & Johnson were worth $3,857,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the business. Norges Bank acquired a new stake in Johnson & Johnson in the 4th quarter valued at approximately $4,139,107,000. Capital World Investors grew its holdings in shares of Johnson & Johnson by 182.9% in the 1st quarter. Capital World Investors now owns 21,195,989 shares of the company’s stock worth $2,779,435,000 after acquiring an additional 13,703,905 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Johnson & Johnson by 10.8% in the 1st quarter. Wellington Management Group LLP now owns 30,556,662 shares of the company’s stock worth $4,006,895,000 after acquiring an additional 2,968,879 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Johnson & Johnson by 7.7% in the first quarter. Massachusetts Financial Services Co. MA now owns 29,526,058 shares of the company’s stock worth $3,871,753,000 after buying an additional 2,118,870 shares during the period. Finally, Amundi Pioneer Asset Management Inc. boosted its position in Johnson & Johnson by 77.4% during the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 4,725,664 shares of the company’s stock valued at $689,332,000 after purchasing an additional 2,061,958 shares during the last quarter. 68.51% of the stock is currently owned by institutional investors.

Shares of JNJ traded down $0.74 during trading hours on Thursday, reaching $142.53. The stock had a trading volume of 157,159 shares, compared to its average volume of 7,245,217. The company has a quick ratio of 1.05, a current ratio of 1.31 and a debt-to-equity ratio of 0.41. Johnson & Johnson has a 52 week low of $109.16 and a 52 week high of $157.00. The firm has a 50-day moving average of $143.95 and a 200 day moving average of $143.96. The company has a market cap of $377.46 billion, a P/E ratio of 18.77, a P/E/G ratio of 3.11 and a beta of 0.69.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 14th. The company reported $2.30 EPS for the quarter, beating the Zacks’ consensus estimate of $2.03 by $0.27. Johnson & Johnson had a net margin of 24.47% and a return on equity of 39.71%. The business had revenue of $20.69 billion during the quarter, compared to analysts’ expectations of $19.48 billion. During the same quarter in the prior year, the company earned $2.10 EPS. The firm’s quarterly revenue was up 3.3% on a year-over-year basis. As a group, equities analysts expect that Johnson & Johnson will post 7.7 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th were given a $1.01 dividend. The ex-dividend date of this dividend was Friday, May 22nd. This represents a $4.04 dividend on an annualized basis and a dividend yield of 2.83%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.95. Johnson & Johnson’s dividend payout ratio is currently 46.54%.

Several brokerages recently issued reports on JNJ. Morgan Stanley boosted their price target on Johnson & Johnson from $160.00 to $170.00 and gave the company an “overweight” rating in a research note on Wednesday, April 29th. Citigroup boosted their target price on Johnson & Johnson from $150.00 to $165.00 and gave the stock a “buy” rating in a report on Wednesday, April 15th. Credit Suisse Group reaffirmed a “buy” rating and set a $161.00 price objective on shares of Johnson & Johnson in a report on Tuesday, April 28th. Zacks Investment Research downgraded Johnson & Johnson from a “hold” rating to a “sell” rating and set a $150.00 price objective on the stock. in a report on Tuesday. Finally, Argus reaffirmed a “buy” rating and set a $155.00 price objective (down previously from $165.00) on shares of Johnson & Johnson in a report on Friday, March 27th. One research analyst has rated the stock with a sell rating, four have given a hold rating and twelve have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $162.93.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: Preferred Stock

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.